Friday September 25, 2020

HSE wants Pembro for all women with cervical cancer

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Susan Mitchell

Deputy Editor and Health Editor

@susmitchellsbp
2nd December, 2018

The HSE wants the state to fund the drug Pembro for more women with cervical cancer.

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Under this proposal, all patients with cervical cancer would be able to access the drug. It typically takes about eight months to see whether individual patients respond to Pembrolizumab, which is called Pembro for short.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Strategy aims to create a health service that can manage non-Covid-19 care alongside surges of the coronavirus

Daniel Murray | 12 hours ago

The plan follows a dramatic increase in admissions at a Dublin psychiatric hospital since the start of pandemic

Daniel Murray | 16 hours ago

'Even if we all go into lockdown, we're going to have twice as many cases in Dublin in two weeks, that's already seeded, the cheque's in the post' — Professor Tomás Ryan

Rachel Lavin | 3 days ago